^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

EGFR overexpression

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR overexpression
Esophageal Squamous Cell Carcinoma
erlotinib
Sensitive
:
B
EGFR overexpression
Non Small Cell Lung Cancer
gefitinib
Sensitive
:
B
EGFR overexpression
Non Small Cell Lung Cancer
necitumumab
Sensitive
:
C2
EGFR overexpression
Squamous Cell Carcinoma of Head and Neck
cetuximab
Sensitive
:
C2
EGFR overexpression
Esophageal Squamous Cell Carcinoma
Z650
Sensitive
:
C2
EGFR overexpression
Gastric Cancer
ASLAN001
Sensitive
:
C3
EGFR overexpression
Colorectal Cancer
cetuximab
Sensitive
:
C3
EGFR overexpression
Gastric Cancer
GC-1118A
Sensitive
:
C3
EGFR overexpression
Lung Adenocarcinoma
Tyrosine kinase inhibitor
Sensitive
:
C3
EGFR overexpression
Colorectal Cancer
EGFR inhibitor
Resistant
:
C3
EGFR overexpression
Hepatocellular Cancer
gefitinib + lenvatinib
Sensitive
:
C3
EGFR overexpression
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive
:
C4
EGFR overexpression
Osteosarcoma
gemcitabine
Resistant
:
D
EGFR overexpression
Triple Negative Breast Cancer
ABT 263 + ABBV-321
Sensitive
:
D
EGFR overexpression
Triple Negative Breast Cancer
ABT 263 + ABT-414
Sensitive
:
D
EGFR overexpression
Glioblastoma
ONC201
Resistant
:
D
EGFR overexpression
Lung Cancer
cetuximab + avelumab
Sensitive
:
D
EGFR overexpression
Gastric Cancer
cetuximab
Sensitive
:
D
EGFR overexpression
Non Small Cell Lung Cancer
cetuximab
Sensitive
:
D
EGFR overexpression
Breast Cancer
vandetanib
Sensitive
:
D
EGFR overexpression
Esophageal Squamous Cell Carcinoma
nimotuzumab
Sensitive
:
D
EGFR overexpression
Glioblastoma
afatinib + enzalutamide capsule
Sensitive
:
D
EGFR overexpression
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant
:
D